Further evidence that Lp(a) testing helps boost initiation and intensification of lipid lowering therapy (LLT), with lower LDL-C and fewer cardiovascular (CV) events, comes from a large pooled analysis of the effects of Lp(a) testing in patients with atherosclerotic cardiovascular disease (ASCVD).
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.